The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy
American Journal of Internal Medicine
Volume 8, Issue 5, September 2020, Pages: 197-203
Received: Jul. 7, 2020;
Accepted: Jul. 22, 2020;
Published: Aug. 13, 2020
Views 194 Downloads 105
Victoria Serhiyenko, Department of Endocrinology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Marta Hotsko, Department of Endocrinology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Alexandr Serhiyenko, Department of Endocrinology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Oksana Snitynska, Department of Endocrinology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Ludmila Serhiyenko, Department of Medical Biology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Volodymyr Segin, Lviv Regional State Clinical Treatment and Diagnostic Endocrinology Center, Lviv, Ukraine
Development of chronic complications in type 2 diabetes mellitus (T2DM), namely cardiac automonic neuropathy (CAN), had been implicated as an independent risk factor for cardiovascular mortality. This paper presents the results obtained during the study of possible alpha-lipoic acid (ALA) impact on the state of insulin resistance (IR), the content of some pro- and anti-inflammatory factors in patients with T2DM and definite stage of CAN. Our study involved 33 persons with diagnosed T2DM and definite CAN, which were allocated to one of two groups. The control group (15 patients) received standard hypoglycemic treatment, whereas the intervention group (18 patients) received ALA 600 mg in film-coated tablets/q.d. in addition to standard therapy. Treatment period was 3 months in duration. Levels of glycated hemoglobin A1c, glucose, immunoreactive insulin (IRI), leptin, interleukin (IL) IL-6 and IL-8, high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha) in the blood were measured. TNF-alpha/IL-10 ratio and Homeostasis model assessment IR (HOMA-IR) were calculated. The significant reduction in glucose, IRI, leptin concentration and HOMA-IR parameters; decrease in the pro-inflammatory link activity, namely hs-CRP, TNF-alpha, IL-6 and IL-8 levels, TNF-alpha/IL-10 ratio, with no changes in IL-10 content after 3 months of treatment was found. The results of our study demonstrated the decrease in the pro-inflammatory link activity after treatment and allow us to consider ALA as one of the promising drug for complex treatment of definite stage of CAN in patients with T2DM.
The Impact of Alpha-Lipoic Acid on Insulin Resistance and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus and Cardiac Autonomic Neuropathy, American Journal of Internal Medicine.
Vol. 8, No. 5,
2020, pp. 197-203.
Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R et al. Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011; 27 (7): 639-653. doi: 10.1002/dmrr.1239.
Spallone V. Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet. Diabetes Metab. J. 2019; 43 (1): 3-30. doi: 10.4093/dmj.2018.0259.
Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care. 2017; 40: 136-154. doi: 10.2337/dc16-2042.
Ziegler D, Keller J, Maier C, Pannek J. Diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2014; 122: 406-415. doi: 10.1055/s-0034-1366435.
Tesfaye S, Boulton AJ, Dyck PJ Freeman R, Horowitz M, Kempler P et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010; 33 (10): 2285-2293. doi: 10.2337/dc10-1303.
Serhiyenko VA, Serhiyenko AA. Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives? World J Diabetes. 2015; 6 (2): 245-258. doi: 10.4239/wjd.v6.i2.245.
Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 2018; 9 (1): 1-24. doi: 10.4239/wjd.v9.i1.1.
Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care. 1999; 20 (2): 369-373. doi: 10.2337/diacare.20.3.369.
Lee SJ, Jeong SJ, Lee YC, Lee YH., Lee JE., Kim CH et al. Effects of high-dose α-lipoic acid on heart rate variability of type 2 diabetes mellitus patients with cardiac autonomic neuropathy in Korea. Diabetes Metab J. 2017; 41 (4): 275-283. Doi: 10.4093/dmj.2017.41.4.275.
Gomes MB, Negrato CA. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr. 2014; 6 (1): 80. doi: 10.1186/1758-5996-6-80.
Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985; 8 (5): 491-498. doi: 10.2337/diacare.8.5.491.
Spallone V, Bellarvere F, Scionti L, Maule S, Quadri R, Bax G et al. Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovascular Dis. 2011; 21 (1): 69-78. doi: 10.1002/dmrr.1239
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia.1985; 28 (7): 412-419. doi: 10.1007/BF00280883.
Rochette L, Ghibu S, Muresan A, Vergely C. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol. 2015; 93 (12): 1021-1027. doi: 10.1139/cjpp-2014-0353.
Ahmadvand H, Jamor P. Effects of alpha lipoic acid on level of NO and MPO activity in diabetic rats. Ann Res Antioxid. 2017; 2: e04. http://annresantioxidants.com. Accessed 04 Jun 2017.
Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud. 2009; 6 (4): 230-236. doi: 10.1900/RDS.2009.6.230.
Suh JH, Wang H, Liu RM, Hagen TM. (R)-alpha-lipoic acid reverses the agerelated loss in GSH redox status in post-mitotic tissues: evidence for increased cysteine requirement for GSH synthesis. Arch Biochem Biophys. 2004; 423 (1): 126-135. doi: 10.1016/j.abb.2003.12.020.
Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic acid. Front Pharmacol. 2011; 2: 69. doi: 10.3389/fphar.2011.00069.
Dinicola S, Proietti S, Cucina A, Bizzarri M, Fuso A. Alpha-lipoic acid downregulates IL-1β and IL-6 by DNA hypermethylation in SK-N-BE neuroblastoma cells. Antioxidants (Basel). 2017; 6 (4): E74. doi: 10.3390/antiox6040074.
Shay K, Hagen TM. Age-associated impairment of Akt phosphorylation in primary rat hepatocytes is remediated by alpha-lipoic acid through PI3 kinase, PTEN, and PP2A. Biogerontology. 2009; 10 (4): 443-456. doi: 10.1007/s10522-008-9187-x.
Packer L, Cadenas E. Lipoic acid: energy metabolism and redox regulation of transcription and cell signalling. J Clin Biochem Nutr. 2011; 48 (1): 26-32. doi: 10.3164/jcbn.11-005FR.
Koriyama Y, Nakayama Y, Matsugo S, Kato S. Protective effect of lipoic acid against oxidative stress is mediated by Keap1/Nrf2-dependent heme oxygenase-1 induction in the RGC-5 cellline. Brain Res. 2013; 1499: 145-157. doi: 10.1016/j.brainres.2012.12.041.
Park S, Karunakaran U, Jeoumg NH, Jeon JH, Lee IK. Physiological effect and therapeutic application of alpha lipoic acid. Curr Med Chem. 2014; 21 (32): 3636-3645. doi: 10.2174/0929867321666140706141806.
Hiller S, DeKroon R, Hamlett ED, Xu L, Osorio C, Robinette J et al. Alpha-lipoic acid supplementation protects enzymes from damage by nitrosative and oxidative stress. Biochim Biophys Acta. 2016; 1860 (1): 36-45. Doi: 10.1016/j.bbagen.2015.09.001.
Serhiyenko V, Serhiyenko L, Suslik G, Serhiyenko A. Alpha-lipoic acid: mechanisms of action and beneficial effects in the prevention and treatment of diabetic complications. MOJ Public Health. 2018; 7 (4): 174-178. doi: 10.15406/mojph.2018.07.00224.
Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009; 1790 (10): 1149-1160. doi: 10.1016/j.bbagen.2009.07.026.
Ibrahimpasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. Med Arch. 2013; 67 (1): 7-9. doi: 10.5455/medarh.2013.67.7-9.
Morakinyo AO, Awobajo FO, Adegoke OA. Effects of alpha lipoic acid on blood lipids, renal indices, antioxidant enzymes, insulin and glucose level in streptozotocin-diabetic rats. Biol Med. 2013; 5: 26-33. http://www.biolmedonline.com. Accessed 20 Feb 2013.
Feng B, Yan XF, Xue JL, Xu L, Wang H. The protective effects of α-lipoic acid on kidneys in type 2 diabetic Goto-Kakisaki rats via reducing oxidative stress. Int J Mol Sci. 2013; 14 (4): 6746-6756. doi: 10.3390/ijms14046746.
Pitocco D, Tesauro M, Alessandro R, Ghirlanda G, Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci. 2013; 14 (11): 21525-21550. doi: 10.3390/ijms141121525.
Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005; 111 (3): 343-348. doi: 10.1161/01.CIR.0000153272.48711.B9.
Serhiyenko V, Serhiyenko L, Krasnyi M, Serhiyenko A. Alpha-lipoic acid: therapeutic potential in diabetic neuropathies. Curre Res Diabetes Obes J. 2018; 7 (3): 555713. doi: 10.19080/CRDOJ.2018.07.555713.